Literature DB >> 11135284

Long-term outcome of critical illness polyneuropathy.

U A Zifko1.   

Abstract

The aim of this study was to describe the outcome of patients with critical illness polyneuropathy (CIP). Twenty-six patients with CIP were studied to determine the clinical and electrophysiological profile 13-24 months after the onset of CIP. Seven patients refused to participate in the study; 6 patients died within the 1st year. Eleven of the 13 survivors showed clinical evidence of polyneuropathy. Five of these patients also had mononeuropathies, including peroneal and ulnar nerves. The quality of life was markedly impaired in all patients. Nerve conduction studies, including limb motor and sensory nerve conductions, bilateral phrenic nerve onset latencies, and bilateral diaphragmatic compound muscle action potentials, were abnormal in all patients. Incomplete recovery within 1-2 years after the onset of disease occurs frequently in patients with CIP. Copyright 2000 John Wiley & Sons, Inc. Muscle Nerve Supplement 9:S49-S52, 2000.

Entities:  

Mesh:

Year:  2000        PMID: 11135284     DOI: 10.1002/1097-4598(2000)999:9<::aid-mus9>3.0.co;2-9

Source DB:  PubMed          Journal:  Muscle Nerve Suppl


  16 in total

1.  Inducible nitric oxide synthase deficiency ameliorates skeletal muscle insulin resistance but does not alter unexpected lower blood glucose levels after burn injury in C57BL/6 mice.

Authors:  Michiko Sugita; Hiroki Sugita; Minhye Kim; Ji Mao; Yoshikazu Yasuda; Mayu Habiro; Shohei Shinozaki; Shingo Yasuhara; Nobuyuki Shimizu; J A Jeevendra Martyn; Masao Kaneki
Journal:  Metabolism       Date:  2011-08-03       Impact factor: 8.694

2.  Review of Critical Illness Myopathy and Neuropathy.

Authors:  Starane Shepherd; Ayush Batra; David P Lerner
Journal:  Neurohospitalist       Date:  2016-08-23

Review 3.  Intensive care unit-related generalized neuromuscular weakness due to critical illness polyneuropathy/myopathy in critically ill patients.

Authors:  Efstratios Apostolakis; Nikolaos A Papakonstantinou; Nikolaos G Baikoussis; George Papadopoulos
Journal:  J Anesth       Date:  2014-07-01       Impact factor: 2.078

Review 4.  [Neurological and psychological long-term effects of sepsis].

Authors:  H Axer; J Rosendahl; F M Brunkhorst
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-10-19       Impact factor: 0.840

Review 5.  [Intensive care unit acquired weakness. Pathogenesis, treatment, rehabilitation and outcome].

Authors:  M Ponfick; K Bösl; J Lüdemann-Podubecka; G Neumann; M Pohl; D A Nowak; H-J Gdynia
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

6.  Role of endotoxin in the pathogenesis of critical illness polyneuropathy.

Authors:  B Mohammadi; I Schedel; K Graf; A Teiwes; H Hecker; B Haameijer; D Scheinichen; S Piepenbrock; R Dengler; J Bufler
Journal:  J Neurol       Date:  2008-02-20       Impact factor: 4.849

7.  Usefulness of a clinical diagnosis of ICU-acquired paresis to predict outcome in patients with SIRS and acute respiratory failure.

Authors:  Anna-Giulia Brunello; Matthias Haenggi; Oliver Wigger; Francesca Porta; Jukka Takala; Stephan M Jakob
Journal:  Intensive Care Med       Date:  2009-09-16       Impact factor: 17.440

Review 8.  Mechanisms of neuromuscular dysfunction in critical illness.

Authors:  Jaffar Khan; Taylor B Harrison; Mark M Rich
Journal:  Crit Care Clin       Date:  2008-01       Impact factor: 3.598

Review 9.  Neuromuscular dysfunction acquired in critical illness: a systematic review.

Authors:  Robert D Stevens; David W Dowdy; Robert K Michaels; Pedro A Mendez-Tellez; Peter J Pronovost; Dale M Needham
Journal:  Intensive Care Med       Date:  2007-07-17       Impact factor: 17.440

10.  Combination of histopathological and electromyographic patterns can help to evaluate functional outcome of critical ill patients with neuromuscular weakness syndromes.

Authors:  François Kerbaul; Muriel Brousse; Frédéric Collart; Jean-François Pellissier; Denis Planche; Carla Fernandez; François Gouin; Catherine Guidon
Journal:  Crit Care       Date:  2004-09-10       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.